Saltar al contenido
Merck

Effects of itraconazole on the plasma kinetics of quazepam and its two active metabolites after a single oral dose of the drug.

Therapeutic drug monitoring (2003-07-29)
Kimiyasu Kato, Norio Yasui-Furukori, Takashi Fukasawa, Toshiaki Aoshima, Akihito Suzuki, Muneaki Kanno, Koichi Otani
RESUMEN

The effects of itraconazole, a potent inhibitor of cytochrome P450 (CYP) 3A4, on the plasma kinetics of quazepam and its two active metabolites after a single oral dose of the drug were studied. Ten healthy male volunteers received itraconazole 100 mg/d or placebo for 14 days in a double-blind randomized crossover manner, and on the fourth day of the treatment they received a single oral 20-mg dose of quazepam. Blood samplings and evaluation of psychomotor function by the Digit Symbol Substitution Test and Stanford Sleepiness Scale were conducted up to 240 h after quazepam dosing. Itraconazole treatment did not change the plasma kinetics of quazepam but significantly decreased the peak plasma concentration and area under the plasma concentration-time curve of 2-oxoquazepam and N-desalkyl-2-oxoquazepam. Itraconazole treatment did not affect either of the psychomotor function parameters. The present study thus suggests that CYP 3A4 is partly involved in the metabolism of quazepam.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Supelco
Desalkylflurazepam solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®